| Natalie Mora, MD | |
|
25 Germantown Rd, Danbury, CT 06810-5036 | |
| (203) 794-5620 | |
| Not Available |
| Full Name | Natalie Mora |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 10 Years |
| Location | 25 Germantown Rd, Danbury, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841606498 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Danbury Hospital | Danbury, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nuvance Health Medical Practice Ct Inc | 4789597691 | 648 |
| Eastern New York Medical Services Pc | 6901049600 | 5 |
News Archive
NYC's hospitals have become a big issue in the city's mayoral race. In the meantime, New York state health officials have posted a plethora of data online about the state's hospitals and doctors.
New research shows that the number of people with Parkinson's disease will soon grow to pandemic proportions. In a commentary appearing today in the journal JAMA Neurology, University of Rochester Medical Center neurologist Ray Dorsey, M.D. and Bastiaan Bloem, M.D., Ph.D., with Radboud University Medical Center in the Netherlands, argue that the medical community must be mobilized to respond to this impending public health threat.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Glooko, the leader in diabetes data management, today announced $35 million in new funding to accelerate growth, expand international presence, and deepen expertise in data analytics.
An eight-year Danish study, which involved more than 2.5 million healthy Danes found there was a higher risk of stroke for those taking high doses of ibuprofen, which is in the painkiller Nurofen. The manufacturers of Nurofen, Reckitt Benckiser, have dismissed these reports. The spokesperson for the company said, "it is important to note that the conclusions drawn by the study authors are based on high doses of ibuprofen…The results of this study should not be confused with non-prescription low doses of NSAIDs, such as ibuprofen, which are available over-the-counter and used by millions of people around the world, for short periods of time, every day."
› Verified 9 days ago
| Entity Name | Nuvance Health Medical Practice Ct Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407898117 PECOS PAC ID: 4789597691 Enrollment ID: O20031205000130 |
News Archive
NYC's hospitals have become a big issue in the city's mayoral race. In the meantime, New York state health officials have posted a plethora of data online about the state's hospitals and doctors.
New research shows that the number of people with Parkinson's disease will soon grow to pandemic proportions. In a commentary appearing today in the journal JAMA Neurology, University of Rochester Medical Center neurologist Ray Dorsey, M.D. and Bastiaan Bloem, M.D., Ph.D., with Radboud University Medical Center in the Netherlands, argue that the medical community must be mobilized to respond to this impending public health threat.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Glooko, the leader in diabetes data management, today announced $35 million in new funding to accelerate growth, expand international presence, and deepen expertise in data analytics.
An eight-year Danish study, which involved more than 2.5 million healthy Danes found there was a higher risk of stroke for those taking high doses of ibuprofen, which is in the painkiller Nurofen. The manufacturers of Nurofen, Reckitt Benckiser, have dismissed these reports. The spokesperson for the company said, "it is important to note that the conclusions drawn by the study authors are based on high doses of ibuprofen…The results of this study should not be confused with non-prescription low doses of NSAIDs, such as ibuprofen, which are available over-the-counter and used by millions of people around the world, for short periods of time, every day."
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Natalie Mora, MD 25 Germantown Rd, Danbury, CT 06810-5036 Ph: (203) 794-5620 | Natalie Mora, MD 25 Germantown Rd, Danbury, CT 06810-5036 Ph: (203) 794-5620 |
News Archive
NYC's hospitals have become a big issue in the city's mayoral race. In the meantime, New York state health officials have posted a plethora of data online about the state's hospitals and doctors.
New research shows that the number of people with Parkinson's disease will soon grow to pandemic proportions. In a commentary appearing today in the journal JAMA Neurology, University of Rochester Medical Center neurologist Ray Dorsey, M.D. and Bastiaan Bloem, M.D., Ph.D., with Radboud University Medical Center in the Netherlands, argue that the medical community must be mobilized to respond to this impending public health threat.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Glooko, the leader in diabetes data management, today announced $35 million in new funding to accelerate growth, expand international presence, and deepen expertise in data analytics.
An eight-year Danish study, which involved more than 2.5 million healthy Danes found there was a higher risk of stroke for those taking high doses of ibuprofen, which is in the painkiller Nurofen. The manufacturers of Nurofen, Reckitt Benckiser, have dismissed these reports. The spokesperson for the company said, "it is important to note that the conclusions drawn by the study authors are based on high doses of ibuprofen…The results of this study should not be confused with non-prescription low doses of NSAIDs, such as ibuprofen, which are available over-the-counter and used by millions of people around the world, for short periods of time, every day."
› Verified 9 days ago
Dr. Shivayogi V Magavi, MD Endocrinology, Diabetes & Metabolism Medicare: May Accept Medicare Assignments Practice Location: 57 North St, Suite 103, Danbury, CT 06810 Phone: 203-744-7007 | |
Andrew Keller, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 27 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7155 | |
Mary E. Blackman, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 79 Sand Pit Road, 102, Danbury, CT 06810 Phone: 203-749-5700 | |
Nirmalamma S Magavi, MD Endocrinology, Diabetes & Metabolism Medicare: May Accept Medicare Assignments Practice Location: 57 North St, Suite 103, Danbury, CT 06810 Phone: 203-744-7007 | |
David D Weinshel, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7173 | |
Dr. Michael Spiegel, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 33 Germantown Rd, 1st Floor, Danbury, CT 06810 Phone: 203-794-5600 Fax: 203-794-5611 | |
Michael Cohenuram, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7742 Fax: 203-830-2090 |